Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Mar;17(3):251–255. doi: 10.1111/j.1365-2125.1984.tb02339.x

Comparison of the effects of prizidilol and propranolol on renal haemodynamics at rest and during exercise.

P L Malini, E Strocchi, E Ambrosioni
PMCID: PMC1463365  PMID: 6712858

Abstract

Effective renal plasma flow and glomerular filtration rate were measured in 22 mild-to-moderate, uncomplicated, essential hypertensive patients during placebo and after 3 months of randomly assigned treatment either with prizidilol (n = 10) or propranolol (n = 12). Measurements were performed at rest and during cycloergometer exercise. For a comparable effect on blood pressure effective renal plasma flow was significantly increased at rest by prizidilol (+9%) and decreased by propranolol (-13.6%); these patterns were maintained during exercise. Glomerular filtration rate was immodified after the treatment with both drugs. It is concluded that prizidilol is an effective hypotensive agent with no deleterious effects on renal haemodynamics.

Full text

PDF
251

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boehringer K., Weidmann P., Link L., Bianchetti M. G., Schiffl H., Reubi F. C. Acute effects of combined vasodilation and beta-adrenoceptor blockade with prizidilol on renal function. Br J Clin Pharmacol. 1983 Feb;15(2):181–188. doi: 10.1111/j.1365-2125.1983.tb01484.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Britton K. E. Essential hypertension: a disorder of cortical nephron control. Lancet. 1981 Oct 24;2(8252):900–902. doi: 10.1016/s0140-6736(81)91393-3. [DOI] [PubMed] [Google Scholar]
  3. Cohen M. L., Smith F. G., Jr, Mindell R. S., Vernier R. L. A simple, reliable method of measuring glomerular filtration rate using single, low dose sodium iothalamate I-131. Pediatrics. 1969 Mar;43(3):407–415. [PubMed] [Google Scholar]
  4. Collier J. G., Pitcher D. W. Investigation of a combined arteriolar dilator and beta-adrenoceptor antagonist (SK & F 92657) in the peripheral vessels of man. Br J Clin Pharmacol. 1980 Dec;10(6):567–571. doi: 10.1111/j.1365-2125.1980.tb00512.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Falch D. K., Odegaard A. E., Norman N. Renal plasma flow and cardiac output during hydralazine and propranolol treatment in essential hypertension. Scand J Clin Lab Invest. 1978 Apr;38(2):143–146. doi: 10.1080/00365517809156082. [DOI] [PubMed] [Google Scholar]
  6. Koch-Weser J., Frishman W. H. beta-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981 Aug 27;305(9):500–506. doi: 10.1056/NEJM198108273050907. [DOI] [PubMed] [Google Scholar]
  7. Larsson R., Karlberg B. E., Norlander B., Wirsén A. Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension. Clin Pharmacol Ther. 1981 May;29(5):588–593. doi: 10.1038/clpt.1981.82. [DOI] [PubMed] [Google Scholar]
  8. Leonetti G., Terzoli L., Sala C., Bianchini C., Zanchetti A. Dose-response curve and time course of the antihypertensive effect of SKF 92 657, a beta-receptor-blocking and vasodilating compound. Clin Sci (Lond) 1980 Dec;59 (Suppl 6):461s–463s. doi: 10.1042/cs059461s. [DOI] [PubMed] [Google Scholar]
  9. Lund-Johansen P., Omvik P. Prizidilol in essential hypertension: long-term effects on plasma volume, extracellular fluid volume, and central hemodynamics at rest and during exercise. J Cardiovasc Pharmacol. 1982 Nov-Dec;4(6):1012–1017. [PubMed] [Google Scholar]
  10. Lüscher T., Havelka J., Greminger P., Tuma J., Täuber M., Siegenthaler W., Vetter W. Prizidilol (SK & F 92657), a new vasodilator with beta-blocking properties in the treatment of essential hypertension. Eur J Clin Pharmacol. 1982;23(5):411–415. doi: 10.1007/BF00605990. [DOI] [PubMed] [Google Scholar]
  11. Malini P. L., Strocchi E., Negroni S., Ambrosioni E., Magnani B. Renal haemodynamics after chronic treatment with labetalol and propranolol. Br J Clin Pharmacol. 1982 Jun;13(1 Suppl):123S–126S. doi: 10.1111/j.1365-2125.1982.tb01900.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mason W. D., Kochak G., Winer N., Cohen I. Effect of exercise on renal clearance of atenolol. J Pharm Sci. 1980 Mar;69(3):344–345. doi: 10.1002/jps.2600690325. [DOI] [PubMed] [Google Scholar]
  13. Pritchard W. H., Eckstein R. W., MacIntyre W. J., Dabaj E. Correlation of renal blood flow determined by the single injection of Hippuran-I 131 with direct measurements of flow. Am Heart J. 1965 Dec;70(6):789–796. doi: 10.1016/0002-8703(65)90334-0. [DOI] [PubMed] [Google Scholar]
  14. Roberts M. S., Denton M. J. Effect of posture and sleep on pharmacokinetics. I. Amoxycillin. Eur J Clin Pharmacol. 1980 Aug;18(2):175–183. doi: 10.1007/BF00561587. [DOI] [PubMed] [Google Scholar]
  15. Taylor E. M., Cameron D., Eden R. J., Fielden R., Owen D. A. Hemodynamic profile of a new antihypertensive agent D,L-3-[2-(3-t-butylamino-2-hydroxypropoxy)phenyl]-6-hydrazinopyridazine (SK&F 92657). J Cardiovasc Pharmacol. 1981 Mar-Apr;3(2):337–354. doi: 10.1097/00005344-198103000-00012. [DOI] [PubMed] [Google Scholar]
  16. Textor S. C., Fouad F. M., Bravo E. L., Tarazi R. C., Vidt D. G., Gifford R. W., Jr Redistribution of cardiac output to the kidneys during oral nadolol administration. N Engl J Med. 1982 Sep 2;307(10):601–605. doi: 10.1056/NEJM198209023071007. [DOI] [PubMed] [Google Scholar]
  17. VANDERKOLK K., DONTAS A. S., HOOBLER S. W. Renal and hypotensive effects of acute and chronic oral treatment with 1-hydrazinophthalazine (apresoline) in hypertension. Am Heart J. 1954 Jul;48(1):95–101. doi: 10.1016/0002-8703(54)90277-x. [DOI] [PubMed] [Google Scholar]
  18. Wilkinson R. Beta-blockers and renal function. Drugs. 1982 Mar;23(3):195–206. doi: 10.2165/00003495-198223030-00002. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES